Oragenics Inc. (NYSE American: OGEN) and Sigyn Therapeutics Inc. (OTCQB: SIGY) announced the signing of a letter of intent (LOI) under which Oragenics expects to obtain an exclusive license to develop and commercialize Sigyn's CardioDialysis™ blood purification technology for traumatic brain injury (TBI) and chronic neurodegenerative diseases. This move complements Oragenics' Phase IIa intranasal neurosteroid candidate ONP-002 in a proposed dual-modality approach targeting inflammation on both sides of the blood-brain barrier.
The CardioDialysis technology, originally designed for cardiovascular applications, is being repurposed to address neurological conditions. By combining it with ONP-002, Oragenics aims to tackle neuroinflammation from two fronts: intranasal delivery directly to the brain and blood purification to remove inflammatory mediators from circulation. This approach could potentially offer a more comprehensive treatment for conditions like concussion, mild TBI, Parkinson's disease, and Alzheimer's disease.
Oragenics is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics through proprietary intranasal delivery technology. Its lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild TBI. The company is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
Sigyn Therapeutics is developing blood purification technologies to address inflammatory conditions. The CardioDialysis technology specifically targets inflammatory mediators in the blood, which are implicated in both cardiovascular and neurological diseases. By licensing this technology, Oragenics gains access to a novel modality that could enhance its existing pipeline.
The LOI marks a strategic expansion for Oragenics beyond its core intranasal platform, signaling a commitment to multi-pronged approaches for neurological disorders. For leaders in business and technology, the deal highlights the growing convergence of medical device and pharmaceutical strategies to tackle complex diseases. The dual-modality approach could set a precedent for future combination therapies in neurology, potentially reshaping treatment paradigms for TBI and neurodegenerative conditions.
For more information, visit the company's newsroom at https://ibn.fm/OGEN and the full press release at https://ibn.fm/VD4RO.
